alector llc logo

Alector LLC

Alector is a biotech company dedicated to the discovery and development of first-in-class, disease-modifying, immuno-modulatory therapies for dementia and neurodegeneration.

The founding team at Alector includes: Arnon Rosenthal, the former Genentech scientist and former CEO of the CNS company Rinat Neuroscience, which Pfizer acquired for $500 Mn in 2006, and Columbia University associate professor Asa Abeliovich, whose lab specializes in neurodegeneration.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.alector.com
Founded2013
Disease Focus
Development StageDiscovery
STOCK CODENon Listed
Address
151 Oyster Point Blvd, Suite 300, CA 94080
San Francisco
United States
Email
Contact Number
+1 415-231-5660

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/alector” connections=”true” suffix=””]

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimers disease. Alector is combining its technology and Adimabs antibody technology platform for the development of antibody therapeutics for the treatment of Alzheimers disease.

Oct 2017, Alector got a $225 million from AbbVie for its work in neurodegenerative diseases. As part of the deal, Alector gets a $205 million upfront payment and a future equity investment thats up to $20 million, with AbbVie having the option to globally develop and commercialize two of the drug targets.

In 2014, Alector entered into a collaborative agreement with Johnson & Johnson Under the terms J&J will fund research for one of the biotechs targets, retaining an option on the drug through proof-of-concept disease model work with rights to negotiate an agreement if it still looks promising at the end of the early-stage exploration work.

In Jan 2016, Alector raised $29.5 Mn in a Series D round financing. Earlier in 2015, Alector raised $32 Mn in Series C round financing. The major investors includes The Dementia Discovery Fund (DDF), Amgen Ventures, AbbVie, Johnson & Johnson, Merck Research Lab Ventures, OrbiMed, Polaris Partners, GV (formerly Google Ventures), Topspin Partners and Mission Bay Capital.